Given the role of TLR4 in the activation of the proinflammatory response during infection, pharmacological approaches targeting TLR4 have been developed with the aim to control host's deleterious proinflammatory response called “cytokine storm” occurring in the early phase of sepsis. The gene discussed is TLR4; the disease is Sepsis.